LT5079B - Avies pararaupų viruso kamienų panaudojimas antivirusinių ir priešvėžinių vaistų gamybai - Google Patents

Avies pararaupų viruso kamienų panaudojimas antivirusinių ir priešvėžinių vaistų gamybai Download PDF

Info

Publication number
LT5079B
LT5079B LT2003009A LT2003009A LT5079B LT 5079 B LT5079 B LT 5079B LT 2003009 A LT2003009 A LT 2003009A LT 2003009 A LT2003009 A LT 2003009A LT 5079 B LT5079 B LT 5079B
Authority
LT
Lithuania
Prior art keywords
viruses
viral
fragments
treatment
virus
Prior art date
Application number
LT2003009A
Other languages
English (en)
Lithuanian (lt)
Other versions
LT2003009A (en
Inventor
Olaf Weber
Tobias Schlapp
Angela Siegling
Andreas Knorr
Claudia Hirth-Dietrich
Gudrun Theiss
Original Assignee
Bayer Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10122451A external-priority patent/DE10122451A1/de
Application filed by Bayer Aktiengesellschaft filed Critical Bayer Aktiengesellschaft
Publication of LT2003009A publication Critical patent/LT2003009A/xx
Publication of LT5079B publication Critical patent/LT5079B/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/12Keratolytics, e.g. wart or anti-corn preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24211Parapoxvirus, e.g. Orf virus
    • C12N2710/24232Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
LT2003009A 2000-07-11 2003-02-03 Avies pararaupų viruso kamienų panaudojimas antivirusinių ir priešvėžinių vaistų gamybai LT5079B (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10033582 2000-07-11
DE10122451A DE10122451A1 (de) 2000-07-11 2001-05-09 Verwendung von Stämmen des Parapoxvirus ovis zur Herstellung von antiviralen Arzneimitteln und Arzneimitteln gegen Krebs

Publications (2)

Publication Number Publication Date
LT2003009A LT2003009A (en) 2003-08-25
LT5079B true LT5079B (lt) 2003-12-29

Family

ID=26006335

Family Applications (1)

Application Number Title Priority Date Filing Date
LT2003009A LT5079B (lt) 2000-07-11 2003-02-03 Avies pararaupų viruso kamienų panaudojimas antivirusinių ir priešvėžinių vaistų gamybai

Country Status (36)

Country Link
US (1) US6685950B2 (pl)
EP (1) EP1303286B1 (pl)
JP (1) JP5037775B2 (pl)
CN (1) CN1455674B (pl)
AR (1) AR029954A1 (pl)
AT (1) ATE324115T1 (pl)
AU (2) AU7063101A (pl)
BG (1) BG107448A (pl)
CA (1) CA2415397C (pl)
CY (1) CY1105408T1 (pl)
CZ (1) CZ200371A3 (pl)
DE (1) DE50109630D1 (pl)
DK (2) DK1303286T3 (pl)
EE (1) EE200300018A (pl)
ES (1) ES2262663T3 (pl)
FI (1) FI20030037A (pl)
GB (1) GB2381454B8 (pl)
HK (1) HK1054329B (pl)
HR (1) HRP20030096A2 (pl)
HU (1) HUP0400479A3 (pl)
IL (1) IL153643A0 (pl)
LT (1) LT5079B (pl)
LU (1) LU90997B1 (pl)
LV (1) LV12990B (pl)
MA (1) MA26927A1 (pl)
MX (1) MXPA03000279A (pl)
NO (1) NO20030082D0 (pl)
NZ (1) NZ523534A (pl)
PL (1) PL366397A1 (pl)
PT (1) PT1303286E (pl)
RU (1) RU2003104525A (pl)
SE (1) SE0300034L (pl)
SI (1) SI21122A (pl)
SK (1) SK362003A3 (pl)
UY (1) UY26832A1 (pl)
WO (1) WO2002004002A2 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19922407A1 (de) * 1999-05-14 2000-11-16 Bayer Ag Organ-, gewebs- und zellspezifisches Immuntherapeutikum für chronische virale Infektionen, sowie entzündliche, degenerative und proliferative Erkrankungen insbesondere der Leber sowie Krebs auf der Basis von rekombinantem Parapoxvirus
US7097842B2 (en) * 2000-11-23 2006-08-29 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
US7628980B2 (en) * 2000-11-23 2009-12-08 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
CN101676389A (zh) 2000-11-23 2010-03-24 巴法里安诺迪克有限公司 改良安卡拉痘苗病毒变体
NZ512341A (en) 2001-06-13 2004-02-27 Bayer Ag Polynucleotides between 15 and 100 base pairs in length coding for parapoxvirus ovis (PPVO)/vaccinia virus recombinant (VVOV) viral genome fragments
EP1499355A4 (en) 2001-12-07 2005-10-05 Bayer Pharmaceuticals Corp USE OF PARAPOX B2L PROTEIN FOR THE TREATMENT OF CANCER AND THE MODIFICATION OF IMMUNE RESPONSES
DE60314823T3 (de) * 2002-04-19 2017-11-16 Bavarian Nordic A/S Modifizierte variante des vaccinia ankara virus als impfstoff für neugeborene
DK1434858T4 (en) * 2002-09-05 2019-04-01 Bavarian Nordic As PROCEDURE FOR AMPLIFICATION OF A POXVIRUS UNDER SERUM-FREE CONDITIONS
EP1765370B1 (en) * 2004-07-13 2009-09-09 AiCuris GmbH & Co. KG Parapoxviruses in combination with other antiviral agents for the treatment of hiv/aids
CN101312737B (zh) * 2005-11-24 2012-11-14 爱库里斯股份有限两合公司 副痘病毒与传统细胞毒性化疗剂联合作为治疗癌症的生化治疗
JP5004990B2 (ja) * 2009-03-31 2012-08-22 アイキュリス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング・ウント・コムパニー・コマンディットゲゼルシャフト パラポックスウイルス・オヴィスの組換えタンパク質およびそれ由来の医薬組成物
NZ599677A (en) * 2009-12-18 2014-10-31 Bavarian Nordic As Production of ifn-lambda by conventional dendritic cells and uses thereof
JP5699093B2 (ja) * 2012-01-05 2015-04-08 アイキュリス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング・ウント・コムパニー・コマンディットゲゼルシャフトAiCuris GmbH & Co. KG パラポックスウイルス・オヴィスの組換えタンパク質およびそれ由来の医薬組成物
TW201919675A (zh) * 2017-09-07 2019-06-01 德商艾庫瑞斯公司 使用羊副痘疹病毒(Parapoxvirus ovis;PPVO)及至少一種額外抗病毒藥之經B型肝炎病毒(HBV)感染之個體之組合療法
WO2023083943A1 (en) * 2021-11-10 2023-05-19 Aicuris Gmbh & Co. Kg Parapoxvirus for preparing for and treatment of respiratory virus infections in combination with antivirals
WO2023083950A1 (en) * 2021-11-10 2023-05-19 Aicuris Gmbh & Co. Kg Parapoxvirus for preparing for and treatment of respiratory virus infections in combination with immunomodulators

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3504940A1 (de) 1984-02-17 1985-10-31 Mayr, Anton, Prof. Dr.med.vet. Dr.h.c.mult., 8000 München Multipotente paramunitaetsmediatoren, verfahren zu ihrer herstellung und diese mediatoren enthaltende arzneimittel

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2714665A1 (de) * 1977-04-01 1978-10-05 Mayr Anton Praeparat zur behandlung von herpes zoster und anderen herpes-infektionen, sowie verfahren zu seiner herstellung
US5443964A (en) * 1987-08-10 1995-08-22 Duke University Poxvirus insertion/expression vector
DE4405841C1 (de) * 1994-02-23 1995-01-05 Mayr Anton Prof Dr Med Vet Dr Multipotente Paramunitätsinducer auf der Basis von Kombinationen von Pockenviruskomponenten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US5648101A (en) * 1994-11-14 1997-07-15 Tawashi; Rashad Drug delivery of nitric oxide
CA2247336C (en) * 1996-02-28 2008-06-17 Bayer Aktiengesellschaft Parapoxviruses containing foreign dna, their production and their use in vaccines
IL126349A0 (en) * 1996-03-29 1999-05-09 Univ Otago Parapoxvirus vectors
ES2125846T3 (es) * 1996-04-15 2001-12-16 Anton Prof Dr Med Vet Dr Mayr Nuevas indicaciones para el empleo de inductores de parainmunidad multipotentes a partir de virus de viruela o virus de paraviruela atenuados, no inmunogenos, como medicamento.
SE9700617D0 (sv) * 1997-02-21 1997-02-21 Kjell Alving New composition
DE19843222A1 (de) * 1998-09-22 2000-03-30 Hassan Jomaa Verwendung von phosphororganischen Verbindungen zur therapeutischen und prophylaktischen Behandlung von Infektionen
JP2003517275A (ja) * 1998-11-02 2003-05-27 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ 哺乳動物vegfレセプター−2に結合し、これを活性化するオルフウイルスnz2由来の血管内皮細胞増殖因子様タンパク質

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3504940A1 (de) 1984-02-17 1985-10-31 Mayr, Anton, Prof. Dr.med.vet. Dr.h.c.mult., 8000 München Multipotente paramunitaetsmediatoren, verfahren zu ihrer herstellung und diese mediatoren enthaltende arzneimittel

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
DHAWAN, S. ET AL.: "Interferon gamma inhibits HIV-induced invasiveness of Monocytes", J. LEUKOCYTE BIOLOGY, 1995, pages 713 - 716
GUIDOTTI, L. G. ET AL.: "Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice", PROC. NATL. ACAD. SCI. USA, 1994, pages 3764 - 3768
J. F. BROMBERG, C. M. HORVATH, Z. L. WEN, R.: "Transcriptionally active statl is required for the antiproliferative effects of both interferon alpha and interferon gamma", PNAS, 1996, pages 7673 - 7678
LUCA G. GUIDOTTI ET AL.: "Viral cross talk: Intracellular inactivation of the hepatitis B virus during an unrelated viral infection of the liver", PROC. NATL. ACAD. SCI. USA, 1996, pages 4589 - 4594
M. KLOUCHE, H. KIRCHNER, F. HOLZEL: "Antiproliferative effects of interferon gamma in combination with alpha-difluoromethylornithine on human carcinoma cell cultures", J. CANCER RESEARCH AND CLINICAL ONCOLOGY, 1994, pages 706
P. LUCIN, S. JONJIC, M. MESSERLE, B. POLIC, H: "Late-Phase inhibition of murine cytomegalovirus replication by synergistic action of interferon gamma and tumor necrosis factor alpha", J. GEN. VIROL, 1994, pages 101 - 110
SMITH, R. M. WOLCOTT, R. CHERVENAK, S. R. JEN: "Control of acute cutaneous herpes-simplex virus-Infection - T-cell mediated viral clearance is dependent upon interferon gamma", VIROLOGY, 1994, pages 76 - 88
STEINMASSL, G., G. WOLF: "Bildung von Interleukin 2 und Interferon- durch mononukleäre Leukozyten des Schweines nach in vitro-Stimulation mit verschiedenen Viruspräparaten", J. VET. MED., 1990, pages 321 - 331

Also Published As

Publication number Publication date
JP5037775B2 (ja) 2012-10-03
UY26832A1 (es) 2002-01-31
EP1303286A2 (de) 2003-04-23
HK1054329A1 (en) 2003-11-28
SK362003A3 (en) 2003-07-01
AU2001270631B2 (en) 2005-07-07
CN1455674A (zh) 2003-11-12
PL366397A1 (pl) 2005-01-24
WO2002004002A3 (de) 2002-10-31
MA26927A1 (fr) 2004-12-20
LV12990B (en) 2003-08-20
CY1105408T1 (el) 2010-04-28
LU90997B1 (en) 2003-01-08
US20030021769A1 (en) 2003-01-30
JP2004517807A (ja) 2004-06-17
ES2262663T3 (es) 2006-12-01
US6685950B2 (en) 2004-02-03
CN1455674B (zh) 2019-03-29
SE0300034D0 (sv) 2003-01-10
DE50109630D1 (de) 2006-06-01
AR029954A1 (es) 2003-07-23
GB2381454B (en) 2004-11-24
NO20030082L (no) 2003-01-08
IL153643A0 (en) 2003-07-06
AU7063101A (en) 2002-01-21
GB0302630D0 (en) 2003-03-12
LT2003009A (en) 2003-08-25
SE0300034L (sv) 2003-03-03
NO20030082D0 (no) 2003-01-08
RU2003104525A (ru) 2004-06-27
CA2415397C (en) 2011-04-26
HK1054329B (zh) 2005-10-07
GB2381454A (en) 2003-05-07
SI21122A (sl) 2003-08-31
PT1303286E (pt) 2006-08-31
HUP0400479A2 (hu) 2004-06-28
DK200300015A (da) 2003-03-07
HUP0400479A3 (en) 2006-02-28
CA2415397A1 (en) 2002-01-17
BG107448A (bg) 2003-11-28
FI20030037A (fi) 2003-03-10
GB2381454A8 (en) 2007-10-23
GB2381454B8 (en) 2007-10-23
DK1303286T3 (da) 2006-08-28
ATE324115T1 (de) 2006-05-15
MXPA03000279A (es) 2004-04-05
WO2002004002A2 (de) 2002-01-17
EP1303286B1 (de) 2006-04-26
CZ200371A3 (cs) 2003-04-16
HRP20030096A2 (en) 2005-02-28
EE200300018A (et) 2004-10-15
NZ523534A (en) 2005-02-25

Similar Documents

Publication Publication Date Title
LT5079B (lt) Avies pararaupų viruso kamienų panaudojimas antivirusinių ir priešvėžinių vaistų gamybai
Zawatzky et al. The Role of Interferon in the Resistance of CS7BL/6 Mice to Various Doses of Herpes Simplex Virus Type 1
KR20180021083A (ko) 바이러스성 색전술을 위한 조성물 및 방법
CN111588721A (zh) 化合物zl0580用于预防或治疗非洲猪瘟的新用途
Ruansit et al. Oral supplementation of quercetin in PRRSV-1 modified-live virus vaccinated pigs in response to HP-PRRSV-2 challenge
Stringfellow et al. Interferon inducers in therapy of infection with encephalomyocarditis virus in mice. I. Effect of single doses of polyriboinosinic-polyribocytidylic acid and tilorone hydrochloride on viral pathogenesis
JP2012121902A (ja) 抗ウイルス薬および癌に対する医薬を製造するためのパラポックスウイルスovis株の使用
JP5636284B2 (ja) フィロウイルスまたはアレナウイルス感染の暴露前または暴露後の治療法
Kumar Novel coronavirus (COVID-19) outbreak: Hope and search for effective therapeutic agent
IL176634A (en) Monoparamunity inducers based on attenuated rabbit myxoma viruses
WO2006108358A1 (fr) UTILISATION ANTIVIRALE D’OLIGODESOXYNUCLEOTIDES ARTIFICIELS A UN SEUL BRIN CONTENANT UN CpG EN COMBINAISON AVEC LA RIBAVIRINE
CN118127004A (zh) 靶向HSV必需基因的gRNA、CRISPR/Cas基因编辑系统、递送系统及应用
CN111686107B (zh) 化合物plx51107用于制备预防或治疗非洲猪瘟药物的新用途
Webster Virus infections in primary immunodeficiency.
Kim et al. Intranasal treatment with CpG-B oligodeoxynucleotides protects CBA mice from lethal equine herpesvirus 1 challenge by an innate immune response
JP2000007578A (ja) C型肝炎ウイルスの陰性化のための投薬システム
JP2000501114A (ja) 弱毒化された非免疫原性ポックスウイルスまたはパラポックスウイルスからの多種有効性パラポックス免疫誘導剤の薬剤としての使用のための新規薬効
SARZOTTI et al. LFN-γ Production in Response to Neuropathogenic Cas-Br-M Murine Leukemia Virus Infection
CN106581052A (zh) 柠檬酸根离子和铁离子在抑制rna病毒中的应用
WO1998037905A1 (en) Arrestable therapeutic viral agent
Martino et al. Treatment of Hepatic Abcesses in Chronic Granulomatous Disease with Granulomatous Disease with...
Francavilla et al. Category 6: Viral hepatitis: clinical aspects 141
CN1628846A (zh) 用病毒类疫苗治疗病毒性疾病
ATAULLAKHANOV et al. Immunomodulator Gepon suppresses the replication of Hepatitis C Virus (HCV) in human cell culture in vitro

Legal Events

Date Code Title Description
PC9A Transfer of patents

Owner name: AICURIS GMBH & CO. KG, DE

Effective date: 20070620

TC9A Change of representative
MM9A Lapsed patents

Effective date: 20140711